mProX™ Human SIGLEC15 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

SIGLEC15 is a potential target for cancer immunotherapy, specifically in colorectal cancer (CRC) and colon adenocarcinoma (COAD). In CRC, a small molecule inhibitor targeting SIGLEC15 was found to induce cell death and inhibit migration and colony formation. This inhibitor also interacted with the SIGLEC15 binding pocket, highlighting its potential as a therapeutic agent. In COAD, SIGLEC15 expression in the stromal area was associated with poor prognosis and inversely correlated with the density of CD8+ T cells. A new immune classification based on SIGLEC15 expression indicated that patients with low SIGLEC15 expression and high PD-L1 expression had the longest survival times. In non-small cell lung cancer (NSCLC), SIGLEC15 has been proposed as a biomarker and a druggable molecule. It has distinctive expression in normal tissues and a high structural similarity to PD-L1, making it a potential target for immunotherapy. In lung adenocarcinomas, SIGLEC15 expression was positively correlated with CD8+ T cell and tumor-associated macrophage infiltration. SIGLEC15+ tumor cells and TAMs were associated with an immunosuppressive tumor microenvironment and poor prognosis. Finally, in breast cancer, osteoclast-derived apoptotic bodies expressing SIGLEC15 were found to inhibit naive CD8+ T cell activation, promoting secondary metastasis. Targeting SIGLEC15 with neutralizing antibodies reduced the incidence of secondary metastases and improved survival rates in mice with advanced breast cancer bone metastasis. Overall, SIGLEC15 has implications for cancer therapy and prognosis in various types of cancer.